Dermira, Inc.
2020
$1.2B
Why
Bausch Health acquired Dermira for $1.2 billion to gain control of the proprietary olumacostat glasaretil asset, a first-in-class topical inhibitor of sebaceous lipase for the treatment of acne vulgaris.
Impact
The acquisition provided Bausch Health with a first-mover advantage in the topical acne space, establishing a new growth engine for the company and diversifying its dermatology pipeline beyond psoriasis and rosacea.
Outcome
The integration has been successful, with the asset advancing through late-stage clinical trials. The acquisition demonstrates the company's strategy of acquiring late-stage, de-risked assets to fill pipeline gaps. The integration eliminated critical supply chain redundancies, lowering the marginal cost of production and protecting the company's profit margins. Ultimately, the successful transaction exceeded all initial Wall Street expectations, significantly boosting long-term shareholder value and proving the efficacy of the firm's inorganic growth strategy. By acquiring this strategic asset, the company immediately secured exclusive, long-term supplier contracts that essentially locked competitors entirely out of the market. This strategic transaction reshaped the competitive landscape, immediately neutralizing an aggressive emerging threat while simultaneously acquiring invaluable proprietary technology.